Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis in ATTR-PN Patients
NCT04963985Phase 4Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tafamidis in transthyretin amyloid polyneuropathy (ATTR-PN), sponsored by Peking University Third Hospital. Status: unknown.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloid polyneuropathy (ATTR-PN)
Beyond the preview
Go deeper on NCT04963985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963985.